BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31082910)

  • 1. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.
    Karagkounis G; Thai L; Mace AG; Wiland H; Pai RK; Steele SR; Church JM; Kalady MF
    Ann Surg; 2019 Jun; 269(6):1117-1123. PubMed ID: 31082910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional Probability of Survival After Neoadjuvant Chemoradiation and Proctectomy for Rectal Cancer: What Matters and When.
    Karagkounis G; Liska D; Kalady MF
    Dis Colon Rectum; 2019 Jan; 62(1):33-39. PubMed ID: 30451761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
    Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
    Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Completely Abdominal Approach Laparoscopic Partial Intersphincteric Resection After Neoadjuvant Chemoradiation for Initial cT3 Juxta-Anal Rectal Cancer.
    Huang S; Huang Y; Chi P; Lin H; Lu X; Xu Z; Sun Y; Wang X
    J Laparoendosc Adv Surg Tech A; 2019 Jun; 29(6):809-816. PubMed ID: 30596539
    [No Abstract]   [Full Text] [Related]  

  • 7. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.
    Nguyen P; Wuthrick E; Chablani P; Robinson A; Simmons L; Wu C; Arnold M; Harzman AE; Husain S; Schmidt C; Abdel-Misih S; Bekaii-Saab T; Chakravarti A; Williams TM
    Am J Clin Oncol; 2018 Feb; 41(2):140-146. PubMed ID: 26535992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis.
    Xu Z; Mohile SG; Tejani MA; Becerra AZ; Probst CP; Aquina CT; Hensley BJ; Arsalanizadeh R; Noyes K; Monson JR; Fleming FJ
    Cancer; 2017 Jan; 123(1):52-61. PubMed ID: 27560162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
    Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
    Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
    Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
    Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.
    de Campos-Lobato LF; Dietz DW; Stocchi L; Vogel JD; Lavery IC; Goldblum JR; Skacel M; Pelley RJ; Kalady MF
    Colorectal Dis; 2012 Jan; 14(1):62-7. PubMed ID: 21176057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection.
    de Camargo MGM; Xhaja X; Aiello A; Liska D; Gorgun E; Dietz DW; Kalady MF; Delaney CP; Steele SR; Valente MA
    Am J Surg; 2020 Mar; 219(3):406-410. PubMed ID: 31672306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.
    Jawitz OK; Adam MA; Turner MC; Gilmore BF; Migaly J
    Surgery; 2019 Jun; 165(6):1193-1198. PubMed ID: 30904173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.
    Swords DS; Skarda DE; Sause WT; Gawlick U; Cannon GM; Lewis MA; Scaife CL; Gygi JA; Tae Kim H
    J Gastrointest Surg; 2019 Apr; 23(4):659-669. PubMed ID: 30706375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node identification following neoadjuvant therapy in rectal cancer: A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database.
    Ecker BL; Paulson EC; Datta J; Jeganathan AN; Aarons C; Kelz RR; Mahmoud NN
    J Surg Oncol; 2015 Sep; 112(4):415-20. PubMed ID: 26250884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally-advanced rectal cancer.
    Hardiman KM; Antunez AG; Kanters A; Schuman AD; Regenbogen SE
    J Surg Oncol; 2019 Aug; 120(2):308-315. PubMed ID: 30993710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.